A vaccine or drug that can prevent healthy, yet high-risk people from developing the memory loss, confusion and other devastating cognitive problems that characterize Alzheimer’s disease is the Holy Grail for researchers, drug companies and patient advocates.
Interest in developing such a treatment is growing as it becomes increasingly clear that physiological changes occur in the brain years, even a decade, before patients experience the cognitive decline that we think of Alzheimer’s disease (AD). What was once deemed “early Alzheimer’s” is now recognized as a much later stage of the disease. And the truth is that dozens of drugs have failed to show efficacy in treating AD and the few available offer only modest benefits for alleviating symptoms. Frustration, paired with new research illuminating the molecular underpinnings and progression of Alzheimer’s is fueling a keen interest in devising drugs that can treat the “clinically silent” phase of the disease; years before cognitive symptoms become apparent. An oft-quoted analogy is heart disease, where preventing atherosclerosis is far more successful than treating heart failure.